✦ LIBER ✦

12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies

✍ Scribed by Torfs, Koen; Feldman, Howard

Book ID: 122868189
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 368 KB
Volume: 21
Category: Article
ISSN: 0197-4580
DOI: 10.1016/S0197-4580(00)83429-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of dimebon on cognition, activiti

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

✍ Rachelle S Doody; Svetlana I Gavrilova; Mary Sano; Ronald G Thomas; Paul S Aisen 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 211 KB

Saffron in the treatment of patients wit

Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial

✍ S. Akhondzadeh; M. Shafiee Sabet; M. H. Harirchian; M. Togha; H. Cheraghmakani; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Longitudinal changes of fractional aniso

Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study

✍ Y. Likitjaroen, T. Meindl, U. Friese, M. Wagner, K. Buerger, H. Hampel, S. J. Te 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 445 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

✍ X. A. Alvarez; R. Cacabelos; M. Laredo; V. Couceiro; C. Sampedro; M. Varela; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB